<SEC-DOCUMENT>0001193125-13-240448.txt : 20130530
<SEC-HEADER>0001193125-13-240448.hdr.sgml : 20130530
<ACCEPTANCE-DATETIME>20130530081625
ACCESSION NUMBER:		0001193125-13-240448
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130529
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130530
DATE AS OF CHANGE:		20130530

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		13879934

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d546056d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>of the Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of Earliest Event Reported): May&nbsp;30, 2013 (May 29, 2013) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 430, Broomfield, CO 80021 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s Telephone Number, Including Area Code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;1.01 Entry into a Material Definitive Agreement. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Public Offering </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;29, 2013, ARCA biopharma, Inc. (the&nbsp;&#147;Company&#148;) agreed to sell to certain investors (collectively,
the&nbsp;&#147;Purchasers&#148;) an aggregate of 125,000 shares of the Company&#146;s Series A Convertible Preferred Stock (collectively, the&nbsp;&#147;Preferred Stock&#148;) and warrants to purchase an aggregate of <B></B>6,250,000 shares of the
Company&#146;s Common Stock ( the&nbsp;&#147;Warrants,&#148;) at a purchase price of $<B></B>160 per share of Preferred Stock, for aggregate net proceeds of approximately $<B></B>18 million (the &#147;Offering&#148;). ARCA Director and Chief
Executive Officer Dr. Michael Bristow has indicated an interest in purchasing up to 781 shares of Preferred Stock for a purchase price of $124,960 and potentially receiving Warrants to purchase 39,050 shares of Common Stock. The Offering is
scheduled to close on June&nbsp;4, 2013, subject to customary closing conditions. Dawson James Securities, Inc. (&#147;Dawson&#148;) acted as the Company&#146;s sole placement agent for the Offering. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each share of Preferred Stock is convertible into 100 shares of the Company&#146;s Common Stock at any time at the option of the holder;
provided, that the holder will be prohibited from converting to the extent that, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of the Company&#146;s
Common Stock then issued and outstanding. Each share of Preferred Stock has a liquidation preference of $.001 per share. The shares of Preferred Stock will have no preferential dividends or redemption rights, and no voting rights except as required
by law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each Purchaser will be issued a Warrant to purchase 50 shares of the Company&#146;s Common Stock for each share of
Preferred Stock purchased. The Warrants have an exercise price of $1.60 per share, will expire on the five year anniversary of the date of issuance, and are exercisable immediately upon issuance, provided that the holder will be prohibited from
exercising the warrants if, as a result of such exercise, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of common stock then issued and outstanding. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The securities will be sold pursuant to a Placement Agreement dated April&nbsp;11, 2013, as amended, by and between the Company and
Dawson (the &#145;Placement Agent Agreement&#148;), and have been registered under the Securities Act of 1933 (the&nbsp;&#147;Securities Act&#148;) pursuant to the Company&#146;s Registration Statement on Form&nbsp;S-1, as amended
(No.&nbsp;333-187508) (the &#147;Registration Statement&#148;), which was declared effective by the Securities and Exchange Commission on May&nbsp;29, 2013, and the Preferred Stock and Warrants are being offered and sold pursuant to a prospectus
dated May&nbsp;30, 2013. This Current Report on Form&nbsp;8-K shall not constitute an offer to sell or a solicitation of an offer to buy any Preferred Stock or Warrants, nor shall there be any sale of the Preferred Stock or Warrants in any state or
jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foregoing description of the Offering does not purport to be complete and is qualified in its entirety by reference to the
Registration Statement and exhibits thereto, each is incorporated herein by reference. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Placement Agent Warrants </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the Placement Agent Agreement, Dawson agreed to act as the Company&#146;s placement agent in connection with the Offering.
Pursuant to the Placement Agent Agreement, the Company agreed to pay Dawson a cash fee equal to 6% of the gross proceeds of the Offering (the &#147;Placement Agent Fee&#148;), as well as a non-accountable expense allowance equal to 1.75% of the
gross proceeds of the Offering. In addition, the Company agreed to issue to Dawson warrants to purchase up to an aggregate of 5% of the aggregate number of shares of Common Stock underlying the Preferred Stock sold in the Offering, or 625,000 shares
of Common Stock (the &#147;Placement Agent Warrants&#148;).&nbsp;As a result, the Company will (i)&nbsp;pay a Placement Agent Fee to Dawson equal to $1,200,000 and a non-accountable expense allowance of $350,000, and (ii)&nbsp;issue Placement Agent
Warrants to purchase 625,000 shares of Common Stock to Dawson.&nbsp;The Placement Agent Warrants have substantially the same terms as the Warrants issued to the Purchasers, except that the Placement Agent Warrants have an exercise price of
$<B></B>2.00 per share and are restricted from transfer for a period of 180 days under FINRA Rule 5110 from the date of issuance. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Placement Agent Warrants and the shares of the Company&#146;s Common Stock underlying
the Placement Agent Warrants have not been registered under the Securities Act and have been issued in reliance on an exemption from the registration requirements of the Securities Act afforded by Section&nbsp;4(2)&nbsp;thereof. The Placement Agent
Warrants and the shares of the Company&#146;s Common Stock underlying the Placement Agent Warrants may not be offered or sold in the United States in the absence of an effective registration statement or exemption from applicable registration
requirements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;3.02 Unregistered Sales of Equity Securities. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information set forth in Item&nbsp;1.01 of this Current Report on Form&nbsp;8-K under the heading &#147;Placement Agent Warrants&#148;
is hereby incorporated by reference into this Item&nbsp;3.02 in its entirety.&nbsp;The Placement Agent Warrants (including the shares of the Company&#146;s Common Stock underlying such warrants) were offered and will be sold to Dawson without
registration under the Securities Act, or any state securities laws.&nbsp;The Company is relying on the exemption from the registration requirements of the Securities Act afforded by Section&nbsp;4(2)&nbsp;thereof.&nbsp;This Current Report on
Form&nbsp;8-K is not an offer to sell or the solicitation of an offer to buy the Placement Agent Warrants or the shares of the Company&#146;s Common Stock underlying the Placement Agent Warrants. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01 Financial Statements and Exhibits </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma Announces Pricing of $20&nbsp;Million Equity Offering,&#148; dated May&nbsp;30, 2013.</FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: May&nbsp;30, 2013 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Patrick Wheeler</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patrick Wheeler</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma Announces Pricing Of $20&nbsp;Million Equity Offering,&#148; dated May&nbsp;30, 2013.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d546056dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g546056g47j00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA BIOPHARMA ANNOUNCES PRICING OF $20 MILLION EQUITY OFFERING </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, May&nbsp;30, 2013</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted
therapies for cardiovascular diseases, today announced the pricing of the previously announced public offering of the Company&#146;s preferred stock. ARCA will issue to investors an aggregate of approximately 125,000&nbsp;shares of Series A
Convertible Preferred Stock together with warrants to purchase approximately 6.25&nbsp;million shares of common stock. Each share of Series A preferred stock is convertible into 100 shares of common stock. Each investor will receive a warrant to
purchase 50 shares of common stock for each share of preferred stock purchased. ARCA expects to receive approximately $18&nbsp;million in net proceeds from the stock offering. Dawson James Securities, Inc. acted as sole placement agent for the
offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each share of preferred stock and its related warrants will be sold at a purchase price of $160. The preferred stock is convertible
into shares of common stock at any time at the option of the holder, provided that the holder will be prohibited from converting preferred stock into shares of common stock if, as a result of such conversion, the holder, together with its
affiliates, would beneficially own more than 9.99% of the total number of shares of common stock then issued and outstanding. The shares of preferred stock will have no voting rights, except as required by law and no preferential dividends or
redemption rights. The warrants expire in 5 years, have an exercise price of $1.60 per share and are immediately exercisable, provided that the holder will be prohibited from exercising the warrants for shares of common stock if, as a result of such
exercise, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of common stock then issued and outstanding. <B></B>ARCA Director and Chief Executive Officer Dr.&nbsp;Michael Bristow has
indicated an interest in purchasing up to 781&nbsp;shares of Preferred Stock for a purchase price of $124,960 and potentially receiving Warrants to purchase 39,050&nbsp;shares of Common Stock. The closing of the offering is expected to occur on
June&nbsp;4, 2013, subject to customary closing conditions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company intends to use the net proceeds of the offering to fund the Phase 2b
portion of the GENETIC-AF trial, and for working capital and general corporate purposes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release shall not constitute an offer to
sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the
securities laws of any such jurisdiction. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has an effective registration statement (including a prospectus) on file
with the Securities and Exchange Commission (SEC) pursuant to which the shares and warrants are being offered. Before you invest, you should read the prospectus in that registration statement and other documents the Company has filed with the SEC
for more complete information about ARCA biopharma, Inc. You may obtain these documents for free by visiting the SEC web site at <U>www.sec.gov</U>. Alternatively, copies may be obtained from Dawson James Securities, Inc., Attention: Prospectus
Department, 1 North Federal Highway, 5</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor, Boca
Raton, FL 33432, e-mail: <U>mmaclaren@dawsonjames.com</U> or toll free at (866)&nbsp;928-0928. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product
candidate, Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride), is an
investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the
potential to be the first genetically-targeted atrial fibrillation prevention treatment. For more information please visit <U>www.arcabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release contains &#147;forward-looking statements&#148;
for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the potential for genetic variations to predict individual patient response to
Gencaro, and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and
performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether
they will be sufficient to meet the Company&#146;s business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company&#146;s
intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s
filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2012, the Company&#146;s Registration Statement on Form S-1 (Registration No.&nbsp;333-187508), and subsequent
filings. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Derek Cole </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investor Relations Advisory
Solutions </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">derek.cole@arcabiopharma.com </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g546056g47j00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g546056g47j00.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`2`#4`P$1``(1`0,1`?_$`+8````&`P$!````````
M```````&!P@)"@($!0$#`0$``@("`P$``````````````0,'"`8)`@4*!!``
M``8!`P,"`P0%"@,)`````0(#!`4&!P`1""$2$Q0),4$B43(5%F%Q4B,*\(&1
ML4)B,R2U%R4V=M'A\8(T)E<8&1$``@`$!`,$"`0#"0````````$1`@0%(3$#
M!D$2!U%A@1-QD:$B,D(4"+'1)!7PL@G!<H(C,T-$%A?_V@`,`P$``A$#$0`_
M`+2/*?E793625QMC634A(J'6-'3\^R$@2,G)%V*YCF#H`$6<:U/NF<Z?[Q10
MIMA``Z]1?W;?=YNF7=-1TUZ652HK-3RJ?6N5*UJ>>X8Z4K45ADX/,S]T]Z?4
M6M2?O=]A]<DG)*U@UFFT_7B,:80TI//O42BSIRJLL7U#ETHJLY$QA[1$RRHF
M4.(%$1W$==<]/07O<]Y4]<W--,^9MYS-XN9][C%]YEO6KJ&CE2X)0%3B<0.S
MR[2,70,)U7J"`]P&,51-8P"B=/<-CD5(8H@/V&#66;!T2O=3>)+55+W)X->A
MXKV''ZC=<KI9JKA*W[#F+XH=G5<%[#`FU37<.5.P2E10:;B<VX!L7N-L4OVF
M$`UZ_7Z-7F:HFD2?+;]2:;P399+N=32I]J3]:$\]/8:J^*_AWDC%O$A[TG#!
MRX;.T0(('`2K(=A]N@;_`"UCNDUMV;,OO[G:JA45Y4SY6^..#.1RNDO%#RUG
MPP\"2OB/RBG;I*IXSR,\"1FU6JBM9L:A").9(&J7E<Q,J!0(19ZFB4QTENTI
ME"E$#;FV$>UK[/\`[M+MO:YKIIU.FEGW$Y845PRDJ9E_M9?%+""AGQ,$=1>G
ME)9)/WJQ1=KSG[IGG#NB2)@("`"'P$`$/U"&NRV$RPG^/CZ>)A:,<3W0`T!&
M/7/<FH]B]R"U\"&\=&^G@:,=5K>@?J"YD<LQK5.>GZ$#(0!EZ>.JZ^_>`^87
MJ*J7]D-@)./YMOT;[[?HW^>V@!H".WE!S!Y)\<)&W3D5P5O69\-U=B,H;)&/
M<I4T\JI%M8\KV7D7E`79K66.;12H+%4$J:VZ:0J=""(@!'3CC^(,@<RW*`QQ
MB#A5F?(&0K.LHA`U6&NU3,\?JHHG<KG!3\/,DBS:-DS*KKJBFDDF0QC&``T`
M\*T\]>:&/X)Y<;S[6N8$ZE&(G>RJ].S%C:Z6"-CT4S*N'BM;A"N9%RFV1*8Y
MP1*?M`.NWQT`J?#3W0>*_-MXM5\<6"7J>4&3)5\\Q7D)@G!6I1LUW!ZY@U$7
M#N*L;=@(?OP:K&71`-U$BEZZ`D3#0!5N]YIN-:I-7G(-G@Z93JXS4D)VRV.1
M;14/&,T@W,JZ>.CII%$P[%(0-SJ'$"E`3"`:`B$3]WY/.MYE,:\!>+^4.6$Q
M#+E0EKZZ<M\88EAA,H)$WC^RSZ"KE)DKV]R8N$FBBH!NF0VX:`65QDKW=DXW
M\52XR<-EE03,L6KESM>/QPVP=WI2RJU:0@#N1#IN*I4NX-^[;KH!AU_]\K,W
M&^^,,;<L>!5GQG8GCAL0B\?D9NK%2+)9VDS4FX"1>5YQ%3<6@4XF$6[M7;M[
M1[3:`L3L7:4@Q9/T/\!^S:O4>H&_=.T$W"?U!T'Z%`Z_/0&UH!)L[Y>K&`<-
MY*S1<5B(UW&U1E[2^*<X)F>*Q[8YH^+0,(#NZEY$4FJ0!]0J+!MUT`WKV]N8
MC#G'QJK>;PA8^K6527G:S=JA&O%7S6MV.&>B'I$'"X`X5;O(I=LY(93J/E$`
MW`-`/>T`-`5S(6&?V2<>+]IGSI>1=JK@!BG<+*'64445!+N\JAC',([@`]=?
M,!;[)=]T[AU-*A3AYDW\S-V*JOEHZ!-KY5P[AZ.-J`PF2I0[\$XR;V*G'/72
M9DD')P`-HV6*8!%$Q_@DN`;E'8I]P$!UOCTJZ;4=TY;172JAO322<R6.&?CF
M8IOE[JZ=?6I1E0ZN.IL)$NJ4_LCQC#3,(X]))LG2B8KO6,<<XQSY%)(%#*_N
M@*GW;;'``'<=M;=VW9=FM,]GK+[6:=NO5#K1JZ2:#FU=)/W9T\X32J/B8]UK
MA5U<E6J--J:2.&2CGZ.TU'F+$G,#(MZZ9K*/;#+G]4Y2.4J,9!-%%'21'2BA
M2G2*LN8IS[AM^[*4-]M15=+Z#7L%5I;4E6O=[MK:BJ:S.71T9IFY>Y0E:]1-
M/>YI:B15\5IRR)>EP2R_C,:'DBDQJ`N(BOI*29R=R3Z42;G,:15)T538HD[C
M)1J1RCL/WEAW.(@`@&M(^K?3JUTND[%M6G\^M7NN?/FF6#F3[W%F2['>YM7]
M55Q6DLO0LH^`B>'XYW`9\Q>'_IEAN<6D)`,45`(JH**A5``1$O>0P@(#UZZP
M7]OM#7[9^XS:5%JKWOWF#78_*GBO6<LW9625FR:Z&,CTO9`GJU]$<K;E4SS:
M1J+*H2I=P-2>0WSE9GZO<7..^6L\V44SM,=5"2EXU@H8`--695/T-5@4"[@9
M1>9L+IL@`%`3`!Q-MT'0%''/V.,^<`^0O%GE+>)>0E,C98AJQRFF)!P0R*J%
MVE["XF+_`$-TJ(_O56["2116`P]W8\[1VZ:DN4&B^_CJ^5_*=`I62ZFZ(]K-
M]J\';(-R0Y3]\=.QS>1;E,)?I!1(KCL.`?=.40^6H*7F'+0!?MI"GJMG*<H&
M*:N3I3%,&X&*:*=E,40'X@(#UT!1S]AQ,A?<IK)0(7M3QYF<J8;="`6*`@`7
M[/H';]6I+N"\"]:`B40V'80Z;AMOM\P#?<.NH*7F4`^89G/';W=,@2&$^Z`D
MJOR0J=BK#&!`4`;2EF<5Z3F(-J@U`-FD@ZF'"2J(`("FN)-MM27+(OZ@N`-B
M.778T_RY'#GRF!--M^Y!5?R&.(`0B'U=PC]T`$1^&H*7F4E^:');*GNU\YZ?
MQ0Q#.O8O!+;(JM,I4>V46_"Y1*#5<&N>9;2U2,!)/T<='.W$>DKN1NT33`/W
MBQQ&2Y02B6^N.7'7%G%K$]8P]B"`;055KK%%-9<J*82UDES))_B-FLCXI2K2
M<Y*KE$ZJB@CV@($(!2%*4(*GF+I^CY?]GPT(&3>X!P\JG-?C;=\4RD;&?GE&
M+?36)+4\*1%Y4L@LFQU81RWD@(==I&R;E,K5^0-TU&R@B8HF(40`<?AF(M]?
MQ!BN!OZ+)"[P6.Z9"6Y&.>_B+`EDB:^Q83`LWVQ/6-SO6YQ*IL'>'7IH!2M`
M0F^Z<A9N6&1,+^VMC:=/#2>38VRYNS),M-E1K^/,?L'AZ9'2)2F`I26J[D1+
MV'VW!`HA\MP(I?X?K/4MA_DQEWB%>U%(P,C(2;V*BWAP1"-RGC%5TQFXT$U1
M#QN92`27`0``,<S(GQZ:`N&?9^D`'^D-]`#0$!6.(M-S)F`)&/:F!TH<#.5U
MDO&(K&V'N*@<0$-OB&OG#Z3633J]T3PJTO\`-F_F9M_?ZA+1EAERK\"3&AG6
M9PJRDI*U&UMXZ,>/4(Y=0'TN0[-HHX2(Q<G;HN@^M(/I$Q^GP#7;!T[DJ:"R
M3:UXK[->%0T=9/"6:53I+3BI6\XI8=S,#7J6:IJTM&2>D3:47%K%YN+A#B(O
MBFWEL[Y2QSSH'TA*.!=NU53@8P"H<1*BGW;>-%`@@0A`Z%*4.GQU@OI9O'2W
M%<-3<%_JY:S1JIIM.65./+*FTI$W'"58>!R2]VM6ZFDIJ/&>:27%<<%'\QU\
MC88)H>--'D)Y'"K=FZ1`P=KML[6(@NW5*&_>4Y%!_4.MMZK<6W*'7H]&@G<L
MM:UI\J<%AADL#@/T]7]-,YDHIOV"4999K>-ZR866FP\84RI`BHIP+)50I1,7
MM?'0:'655Z;"!E-@^`!K%?5NW54]-5TM%6V;0LG)[U*YDM69\7S?$F^,'F>\
MVU-(GRS4VI.^V+]?8,9IL:1IG?%X@\8+"-Z@P_RJIU"F_P`T!?I.9(@"/U:Z
M\^GMIT*/[E]I34E5+'Z[0PSAA/ACG#*)E^YZZ_Z37J$%Y67AD3=C\1_6/]>N
M_DU8SQ/-`0>>X;:8KDGS.XD<`E)N,:T&"GVW)_DN9_)M(^//4Z.H=S1J?(K.
ME$B"I.R!!,=`P[G*X1/L)0T`7???Q11\X<-#9`K%AJ$G=N/EE:7..:1E@@UW
M[JF3`H5^Y131L@\%9<J2"K5X"9`$=F70/EH#X?P_/)7_`'6XH3.#YR1]1:N/
M-A-&QJ*ZN[I7'=M4<R]=,0IQ%0Z$5*%>M-_@0A4R_9H">S0'!M7_`"M9O^G9
MS_2W6@*#7M%9?B\&\[HC(,S3\CWF/95#*L:M`XJIS^]V\WXFR%$KY"N1ABO'
M$>R$G<X4)OXB#N(#J2Y?"BP_FKW_`'C%04Y:M47&N9K%EALL$6TJ>0JB.)XV
M(G7(E19A<'ME=A)1$:W<*E,X$&PF\0"("`?4$%+S"CP>]I6WO<^O^=W-^RU:
M\9<M5J7RG5<<T]V6;ID'8IE4LC%V&8G2[M)P81N=,(UJU[V:8$34,HJ)0T!+
M3SFN$K0>&W)ZXPBBJ<S!X1R&XC%T?\9N\<5U\Q2=IB'4IVPNN_?Y;;Z`JA?P
MZ52C)[FO=[$^("CZC8`LTC#',`',D\GK+5*^[7`3=0.,<\5)W!U'R"'SU)=P
M]1=F^'3[`VU!2#0`T`-`<V9F8RNQ$K/S;Q&.A82-?2\Q(N3@FW81<8U5?/WB
MYQZ$2;M4#&,/R`-`0G>UW:H/.&3.5GN%9"LE?BY7/E]6QSAR/FY^)9R%?P5C
M)Q^'0Z+=J[=)K-$IM\DFJH':'D5;B8=P,`B!!O[GT6;A5[HD'R2Q'(Q3F'M-
MBJ^?8$\!),G[4)UO($99$@''X:NJFW+*NFBQC)&V$Z3[?;MU)=+\)=8QS>Z_
ME&@4K)%4=)O:W?:K!V^#<HG*HFI&ST<VD6P=Y/I\B17($,'Q`Q1`?AJ"IYAS
MT(*]=&DV3>75!VY.BD1XOW(H(@LX.'F,&R9C&30(/7H(F']0Z^9OIY=;5:]R
MZDU9,Y5YDW=\S-SKQ3?5:4L,^5?@2-XDM[8YR-H.)BH]L@@"LO8)U09%PT8=
MH$7,<Y_$U;"N!NPJ*91.83;!OKM+Z+[KMDFM+I66U6W1\Q?K:Z>:,DFF^+3]
MU16>&)@O=%MFQ<SF:BTDOXQ\7`*$G@><;RXV/#T[%+UR?F'B;"MV%TI%OF[L
M#'6<)1*X).$74?N83$!7L.F'3<>FN%W;[;=PT5^U-S=&Z^U:VV*S4G=-1U>I
MR>9KS3-S<CF>HG*YF^6"6$,#]]-O2WJA5NW)2S1EE2YEQ62?;C`4RF4Z0K:D
M=9<C6**(4CU=E'-H<RLK',9IJF8R:\VY,FW$4FZX`8$TR&)N4!,.P:ROL/8U
M5MATNZ>IMQT:36U=3RZ&EH7YM-3:\KA-/JSN/S)QCAW'';I=J6OE^BM=+-CE
MVM?G`(66[>U,X>M+-"-$Y$A043FH)8&@OT52B*#WP[.&#]%<@]Q3AVF$.F^X
M#MCGK+N^UZ=15TF[:266^\K\NNHES)+A,Y5A%J#?I/=;:M\RFC2-Q?!\'Q[\
M'@-$QX]0<9\Q9Z=?SI&O,*!>Y,4U"`5SU\I-SDW'^Z8P:TCZ1U%%6_<CM.JI
M)G.U7:&+S?\`J8M=KS?>90O=,Y=DW!S9^5CZ8$ZIOO&_6/\`7KZ&,\34U9!7
MNMQ@,>4^U7RUOTHNL4RNS-IL$@N<A$FD/!,%I*06,)Q`!V;-C``?$1$`#KMH
M25_O;EXIXNY\-^0W/'EOBJ#R0[Y$9>E0Q%"7!)\X0JF,:4*D%&?AB:;MN!4W
M1TRM-]Q#LC@$.AA$0)(9#VI?;RD&#Y@GQ5QBP4?,G3,CYDQDTGC(SI!1N#QH
MI^*&!-TU%3R)FVZ&*`_+0%6KV[+Q.>W?[J<KA2^/5(^MS-WL?'FYK.5!0:.&
MLK*`ICRR*]P]IVYI$&*Q%1WV2<GZ[:DNA&4O.;"'0?B'0=04G!M7_*UF_P"G
M9S_2W6@*.OL.B(>Y77=O_C[-/^FE'^O4EORKP)N??$]O9+D1B)?DGBVO)KYO
MPY%.'%D9QC0OK\B8Q:D.XD6*Y42"K(3=/2`SMD(@90[<%D0WW(`05/,1'V&O
M<1"_UA#A?EV?!6ZTN+6>80G)1R<7%GI;,H+O:0JY<"*CB7JI!%1D4PB=2/W(
M'^`&X%A',V.V67L19.Q3(F*DTR30+;2%5C[B5L-D@WL6DY$"@(B#99R4_3]G
M0%(#VGLD/.$_N61>/\O`I4OQM[<..%\+)B+-&)L$A(()5UR^%02)%8*6R%9E
M!4VR?A=`H`[==27<"^6`"``!@V,`!N'V#\]05/,&A`/Y!_XCL`:`2?$&;\:Y
MXA+)9,66#\T0%5O5IQS)S*+%XUCE;337A8^P-XIR[11)+L&CPWC*[;][=4P#
MV&'8=`1F^\[G*PU7CW5.,>,EU1S-S,O,5A>KLV9O^(-JH_?,4KI*@5,14105
M;NT&(G^':[./]D=`+'0_:2X"56D5"LSW&O'%LG("LPD/-6>4922LC899A'-V
M\E-/CEDDR&<R3XBBQMB@`=^P```&@(T?>*]L;CQ1^'\UF'C;A>K8WM.(K%&6
M6TFJ;9VBK-T.0,,/.IO2N'CD#IP[AX@\`2@`E(F<=]M26R\/0+/_``^_)8,K
M<4)K!DW(^>T\=K$:,BVZRH&<*8XMJCB7K)TRF^LZ$3)%>L^G0A2)E^S4%;S)
M[M""O5EJBR^(\F6&KR!%4DVTBLZB71@-XY"$=J&7CGJ*IB@58IDC=BFV_:J0
M0'7S6];NF=XZ.]2:G9]<F].C;GM\SSU:>?WM29\9FFWBXFY.U[U1[@L-+54O
MQJ:#6>*S4>(<:MDMP5NVBDE`1:%53,+<!$?.X$P%!R[,`AYCE'[H#])`Z!KD
MNR.KE13TM-8Y</,F@TOF_O+CXQ/4W7;CU9W6M>ZF_P`1ST)F5!.PU%!!S_PZ
M`68,D0`P`"I@6*I(.Q#?[SI94XC_`'2E#6W%DZYV_5W);*:W0_:K=/+-/#)-
M0YO1C$X+5[1\REGFFQ<S>>)PG.6TUF=@A5W8*(RSA21:=Q]O!+LU%EDSD-O]
M/JVQU$A_2)=>LK>M5NUJ"YV=-M5FKJ5DF/PJ2:9^ZN$>,#]TNV7]3IUDN'+(
MEAAP0VNVY)<R+0T>HJ9P@D"AF>X]RC,YQW.1$3`?9NJ;J=/[O=]0``]=:A[V
MZNU%]H9J33;]Z/%Q@<VM=B^E?/!8X^L-O$ND2][S=6Y-%`XQ%/=!99I\!!\#
M8K4IRL&QE!Z`Z>/1*!"]3"4IA'H&LD_9?TZN^^^MM%=Y4W9+(U453[-=8Z4L
M<U%<#UW4J\TEIVIJTGSUTO(O3D3=2THQ@XJ3FI)4R$9#Q[V4D%R(K.#(,(]L
MH[=K%;MTU7#@R:"1A`B93*'VV*`CL&N_N+>+S9JE*N652]B@5BO=A]Q>9Y"X
M/F>.'#[%V=+C$WQ1!+)63?\`:+(4'"&K#-?U?Y6KJ4C!-922-.NTDQ>.#)))
M%:E%,HG%0>V2]+B2>^VGRBP#;\,X5XXT2OY'QY?<>8B@X^6Q_?<7W6J*,G-9
MCV36U/$K%(P:%:D@=33D[@#$=>1;S;]O=W`$%+S)#<FY*I^'Z+8,D7U^\C*C
M5VJ3R9?1\-,6!X@@LY19I"A$0+*1EGICN7!"]J*)Q`![AV*`B`%('W5YA#E'
MS#<YOXKXDSG)0JE1IS>?MJF(+U`DE[W6G#HB,Y#-'4&D_`C>+29)BNJFF959
M'<`$H`89+ED6%>$_NPUO(U1QYCKDQC;,^'\[J%@J?(/)C$M^=4>Z3J@HQ+*<
MCYUC!N201YM<"*+HOBH)H+*&V4,F'<$%3S'!<MO<=PGQ^3R'C;\M9?R3EV+@
M'K!O1\?8HO$ZU4EYF&,I$H.[<2&)5F[0Y':9UE2.5A2)W`!3'#MT(*EGMKVO
M)G#+E]3,]Y/X\YV?45&*N5;M/Y>Q?;G<K%,[E'*-@EV#)S%-B2!8QT!#G1[R
M'41[NWZ@`!DNA%%W'CYR;Q%RCKDW8,5NK,]CH%XVBK`PN-$ME&D6+M^U.X39
MN(NWQ$6J[*JU[NXR(+)A]T3`([:@J>94-]T3@GE+A/RYKF=.+<!;B4F]VDV0
M\<.:)!RTNZQKD6,>$D)JK&;1#5TJWB3K*>H9E.'B4:KJ(?`FI+9<B>7C#[O=
M%R!5:E#\CL09UP5EEV6+B)CU^&L@RV/YR:<';L/Q6"L$1`.E(UC(NS@H*+Y%
M$6P'[>]0I>_4%3S$[]U#V@F',-\.><"OX>E\BV;%JC,L)%0T76LK-(],/PLT
MA(HD.I`7*/1(1-O("0Q%DRE(MV"0BI1`EO%3W1LM\8XJ)X_^Y_A_+&-;#4T&
M\!7^0!J=+V&LV:*9@#9D>YO81N^;KOFZ!`*$K'J.DGA`*95,BG<8P$F)O=&]
MO8L6$P'+3$2K04A5*@WFG3F7,4"]PD""18'F17#?_#\'?OTVT!%1S=]VG).9
MZ78<->W3AC..0)"TL'4+.YU98QN#5A$Q3PAV[Y''C$\4#U>5=M53$+(N2H$;
M%,)DR&/VG"2U+!-CUN*-VQW[;WM[\9:]GIE>*_9IJM2,O*5F`H%ONUQ>WJPN
MGEQL$6\B:U$R3EG)LR2::2AGAD2>0O:)]P':"MYD-J?,^R99]U+''+_/O'?D
M#7..>*8F=J>*HL^)KC-25*2<14BA#W>:B&42L=:1D9M^=Z\*V%51L`I$)Y/`
M`C)8E[I:[P_EZB9SH43DC&\A)2=3F%'K9DZEZ]/5=^*\:Y,S>I+PUDCXR5;F
M1<$$-SI`4_Q*(AUU!6\QK/-_E5QWQ%1[IB',;*^VB4R-C.R-D:+1\8W6\O)^
M(G6,E!D1(]@X5Y!LEEW6Y2^H<I&2$"G$`#81$%//V[<M\E>!?(1KE]IQVS=9
ML<SL4[J&2*JVQ_;&KV6IKMXB\;OHY9:((S"P5]V@1RV!0Q4E#`HF)B@H)@DN
M2C+WEL+_`/77A]^4/S+MG3\5\&_^W_\`]?<K?GKU/@\OH?0?EO\`"_-O]'D]
M9X>[KW[==.)7\WB/FRGAB@9?BT(VYPP.5613FC9AF?TDS%G.("(LWY"B;Q'$
MH"9)0#IF$.I=89ZJ=%NG/6*QNV;YI9:C56FU+KRI25<B[)6ES0[LCW5DW)=M
MNUDM7:6W*GEG*_\`#D-`6]O*LE<BM&Y-LK1'<PID6AHQPLF`B(@'F(NV(;;?
MX]@:TUU_Z:^S9:E:MMW!7Z<F<J=/31E7!1A'!04<V9&?6N[M0GHY6_'/U&TV
MX$1[,Z:B65IH#)'!0@_E]D;8Y1$0$=WPZFD_IT6:AF<U)NNN4S>/Z?2]L)CQ
M_P#7:UK&BE]OY'R5X!1RH!OE:=`0,!@,6O,MP'[0W>]!U^:;^G%9YIG,]V5_
M,X_\?2R>:^++NR/+_P!CJUA]%+[?R,F'MYU`KHJ\SD.S2#4#]ZK5I'1T>JN&
MX")/5"H[,B4WS$I=]?OMG]-OISIU:J[]>[C5R+A+(I%[(_@3J]9[[++^FTM-
M.'9'^Q#T<=XTIV+().NTN&;Q4>!@6<G+NJ^?N=A`SN2>J[N'CDWVG$0*'0H`
M'36\'3KIILSI58=+;^QJ-4])/,N?4:3GG:PYIYH1F?9'+@8MO-ZN-^K/JJ^:
M9J+>.2CV+)(/^_S_`)]9(RP/7&K)2K&&9JR$M(LXQ@W(91=X_=-V;1%,A1,)
MU%EU$R$*``/]&@-A-<KA)-9)0JJ*R::J2I!`Q%$E"@=,Y#!T,0Y#`(#\!`=`
M`QBD`!.)"@(@7<YB``F/])2_6(`83;[;?$?D`Z`^OD/^T/\`3H#P3F'H([A^
MG8=``#&+\!V^W8`Z_K'XCH#WR'_:'0'S44*4ICJ&*4H`)CG,)2%`"AU,<YA*
M4`*'S$>@:`THV7C)9%1S#R3*3;I.%V:KB/=(NT$W;4_C<MC+('43\R!^AR@.
MY1^.V@.CY#_M#H##0&L\9,I%N=G(LVD@T4`0.U?-D'C8X#T$#H."*)&`0$0'
M<!T`1V^(\3M70/FV+L<MGH&\@.V]'K"3H%-^[O!P2+*L!M^N^^^^@#\@DDU2
M*@U22;($^XBW2302(']U-(I"!_,&@/J!A`=P'J/S^(_TCUWT![Y#_M#H##0'
MH&$OP';].P;]=MPW^.P[:`R\A_VAT!YW#OOT[OVNTO=]GWMM_AH#'4<LO-SP
M7/V\?7F$VL@:GC'B3%@UX\DBR2]0BP:<LO8A%@UY)PP1`-!W<`:`8AR7_*EW
MR]BN@3JT<QB:H@YR'D.<?.2H-XRL,5"`TBW9U%"H`25<DZ$$#',)P[?CMH!W
M](OE-R)"_CU&G&4]"I.EXTSID"J::#IGV%4:F272163$B9BB7<H`8@@(;@.@
M$SRXEB._2U6Q1<[<M'V9>=96""@X26<,99R]C$E5TTG9VJ2J:"*J)A$I%A(<
M>AB=0`=`+;)2<;!QSJ5EW[2+BXYN*[V0D'*;9HU;I%#N57<+F*0H``?$1W$?
MM'0!9JN1:9=5W#2MSB+]VU:MWZC51L^8.31KLQDVLHW;R+9HNZC'2A!*FX3*
M=(PAT-H#BYBR:PQ'CZP79TDB]<1C8A8J)57!N>8E'*Z3=DQ2,`&5^M57<XD`
M1(0!'0'.Q7F2JY+9-62$K'(W=O"L).R5-$LB@ZB%7221EB-TI9FP=/&K=14"
M"J4ABB(!UV$-`%/E=/,('!=R%VT2?/)I-E7H)FJ)]U9R7<D;LE$@2,54RS4O
M>J7M$>I/@(:`TL+6?%N.:_0L&H6^&-=V<0DD[AT%%%CN;"X3/(S2!GJ21F)I
M%-THH!D?+Y"]H`(`.@',[#\@$1^P`W']>V@$QL&9L8UF2CH:4N$6,Q*R[:!8
MQ,<967DE95VH"2+;T<8FZ5)LH(`<X@!$Q'ZA#0!PL]HKU,A75BM,NR@X9DGW
MN7S]7QIICUV3(4H'575,("!2IE,8VW0-`$9#.6)7+ZHQB5ZA#R%Z10<59F"B
M_J)1)T8R;8?&*`&:&<JIF*F"WC$XEZ:`-UQNU3Q_#JS]SGF%?B4C`F+IZ<^Z
MBIMMD6[=(BCERL`#N)4R&$`T`5W&:\4MI>N0*UXA0E[:FQ4@&1%%E#O"R:)5
MX\%5$T3),3O2'+XBKBF8PF#H&^@-ZN98QU;;+*U"MVR*F+'"-CNY*-8G65.B
MW24316527\)6KLB*RH%,*1S[".@%!,8I"&4.8I"$*8YSG,4A"$*'<<YS'$I2
ME*4-Q$?@&@$X3S!C5Q:8BE,;=&2EFG/5C'QD0964,)6*9E7*CIPQ36:L4B$(
M.QUCD(80$"B(Z`4G0`T`-`#0`T`-`#0`T!\'+E!DV</')^QNT;K.G!Q_LH-T
MCK+&_P#*F01T!'AB_P#+,L?(/*W)1/Q;\RV)Y'8WJ*A2/E7B$*Y/'P35A%;*
M#(R[EP0J39,"B"0@978!'N`!S_';'TCC>@N1L23=A9+C89B[V..0$GI(1U-J
M`LC$)B39($HIBDFF<P;%[BF^0:`0K#1*OD3.]BR*@1)*"K2D[6<7,1\KMY+O
M"+BO=[X^7-Y5MG3MT"""JYN@"!"#]`%T`;<V-7F0<ZX9Q`\[_P`DF:2>0[.R
MW,#>?-`*[,(UT4H=B[5!RF43$'<!\G70&-#<N+_RFO%Y@R_^Q\>TY'&R$BW`
M`CY2:]65V_:,E$_W+A*,5\G4FY2[`'SVT!R,ZQ<3DKD!A;%@M&KD\:9>_P!Q
M<]@J.$X&&,HI&1!C;B":+UT4W>!2@)N\HC\M`="KLE;WR]M]_AR`-8QS3$*$
M[DT=BMI:TN2J*NHY!8FY'1HHC@Y51`1*F8@`([]-`<KD''JY7S+C/$+>2-&5
MZKME\F7V327*@6/9)*`SC"&<G,5)NZ7*!BI&-L)!5[P^&@.Y8Z/$VG/.'86H
MQK%M5L-Q3^V3KN.*06B#N:`$Z_$F=)[@YD)`S87)^XQCF((J&'ZMQ`..5+X6
M0OU>PTVG$JRS?P+VYY#L/K",73.G1YA13A8UT<Q3-GT^X*)5%2#Y$6X&$FQC
M;@`A^/)NJ96Y`,9:.8-8?'N'B.ZIC*)*S%%:;N+UN=>5F_2%3%=%O'1S8ROE
M5^X`HF4$#J=0%(YAR`)4"+K\6R))7B^S25'J*)Q,HJW":\03CQNB4?$"GH$0
M2\PE$R9%AV,`".@%4QEA2H8^J53@UHF+F9FO$:OEK`^8-74@>?*V*BL_:.ED
MU%6Q6Y1\2!2"!4TB@`!U$=`(+RCCULB6ZEX2J9"&MER1*YM$NH8[DM6Q_'.B
MNEU`2.8Z3-64?)`)Q*4%%@2(01$H@``)P^H]6OF34:DR.$5@OC)'G>6^=\@$
M=62VE;%<RB+B4(*;A=R*+7L<*`<3$(F8I1+WD``%2XNIQ]OLUXS$^;-6$U;V
MK1E4:^U;%33JV+XM<8^`14\"16S5>8.R\A4Q$%#I)]X%[3;Z`,]QR!`VS(ML
MJ-@FDHG&V)8R.D;NV!<4W5SLTF3U$97/`D8KIW#QZ*8'502W]6Y$$S@)`$!`
M)G'"6CLFY)N.99%JWC7,HP/5L:5U)N3R0U$KRP-WC]<C8@(-#R3TX)EW$H&,
M"A4P$`'8![_QZ_;H`:`&@!H`:`&@!H`:`P5217160<)$617140524*!TU$E2
MB11,Y1Z&(H01`0^8#H!,*?A7%]#>A(U:HL8YVFJX6:J*+OI`L>=R(F7_``E*
M1=.D8@%1,/=Z<I!'?XZ`4Y9)-PBLW6("B+A%5!4AM]CI+$,FH0=A`0`Y3"`[
M#OUT`2Z+C6C8SCE8JC5QC7V3A45W!6XK+.'"@G,INX>.E5W2I2'.(E*)^TN_
M0-`;%HH=6N1V*\_''7>1A7:3"09/G\3)-FL@F5%^R3D(ITS>>B?)%`JR7?V*
M;=0T!DDE3,95@J21(BHU.&3,.Q"D9L&A3B)CF$=S*+N'!]^H]ZJIQZ[B.@&=
M8%B*IG"\9BRK8%EEY.2LA8&JLFDM)P<]!U"*:^F05`T:Z8R#=G-$7`A@$035
M`@@8-]`/<@:]!U:*;05<BF<-$M._PL6*)442G4-W*J'V`3K+*G^HZAQ,<YAW
M$1T`69/&%"F7%N=2E;9.W5\BF\';71CNBN9F):$\;9BLJFN0R**!0#M\7CZA
MOU'0'8J5.K-%A4*_5(AM#1;?82H-_(<ZIBD*F"KERX.JZ=+=A0+W*',8"@`;
M[=``+T]B7'-HMT7>[!4XR6M,.W3:Q\F]!98J**"IED`,R%7T+A1NH;<AE4SB
M7Y:`VJCC"A420G):IUIC#R=C>N)"8?)>99RZ<.E17<`19RJL=LW46'N\27C3
MW_LZ`Z\G4*U,SL!996&9OYRJF>'KTBY!4ZL4I($!-XJU3\@(%563*!>X2"8`
M#H(:`,O\O^[0!7:TNK,K1+75K#-$;7.,6T9*3H>4SYU'LP*#9GWJ*'(@@D!`
M'M3*3<?COH#DML6T!C5I^F,:PP:5NTJR*]@C$!<)EE%I;;\17<N07%V*[CM#
M8_?N4``"[`&@.Q4:95Z'"-J[489G!P[0-DF;0IQ`QO@*JZZQU7#E80``$ZAC
M#L&@"N?#.,%;9,7E:GQ:]JGD%&\I+.`<+JK)K-?1+F1147],T75:B)#*I$*I
M_>`>N@.U1L=TK&L2,)1Z^T@(XZ@K+)MS+++.%=S"!G#MRHLZ7[.\>T#'$I=^
+@!N.@#IH`:`__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
